Secondary Logo

Journal Logo

Most Popular Articles

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics. 26(2):66-73, February 2016.

Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes

Tshabalala, Sibongile; Choudhury, Ananyo; Beeton-Kempen, Natasha; More

Pharmacogenetics and Genomics. 29(7):167-178, September 2019.

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

Hung, Shuen-Iu; Chung, Wen-Hung; Jee, Shiou-Hwa; More

Pharmacogenetics and Genomics. 16(4):297-306, April 2006.

Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1)

Fujita, Tomoe; Brown, Chaline; Carlson, Elaine J.; More

Pharmacogenetics and Genomics. 15(4):201-209, April 2005.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

Minami, Hironobu; Sai, Kimie; Saeki, Mayumi; More

Pharmacogenetics and Genomics. 17(7):497-504, July 2007.

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver

Girard, Hugo; Court, Michael H; Bernard, Olivier; More

Pharmacogenetics. 14(8):501-515, August 2004.

The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation

Nenonen, Hannah A.; Lindgren, Ida A.; Prahl, Alexandra S.; More

Pharmacogenetics and Genomics. 29(5):114-120, July 2019.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis

Zuo, Xiao-cong; Ng, Chee M.; Barrett, Jeffrey S.; More

Pharmacogenetics and Genomics. 23(5):251-261, May 2013.

TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity

Thiesen, Signe; Yin, Peng; Jorgensen, Andrea L.; More

Pharmacogenetics and Genomics. 27(6):213-222, June 2017.

Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole

Miller, William R.; Larionov, Alexey A.; Renshaw, Lorna; More

Pharmacogenetics and Genomics. 17(10):813-826, October 2007.

Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

Griese, Ernst-Ulrich; Ilett, Kenneth F.; Kitteringham, Neil R.; More

Pharmacogenetics. 11(1):69-76, February 2001.

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan

Sai, Kimie; Kaniwa, Nahoko; Itoda, Masaya; More

Pharmacogenetics. 13(12):741-757, December 2003.

Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function

Leabman, Maya K.; Huang, Conrad C.; Kawamoto, Michiko; More

Pharmacogenetics. 12(5):395-405, July 2002.

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited

Ozdemir, Vural; Bertilsson, Leif; Miura, Jun; More

Pharmacogenetics and Genomics. 17(5):339-347, May 2007.

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis

Suvichapanich, Supharat; Fukunaga, Koya; Zahroh, Hilyatuz; More

Pharmacogenetics and Genomics. 28(7):167-176, July 2018.

Estrogen receptor alpha gene variants associate with type 2 diabetes and fasting plasma glucose

Dahlman, Ingrid; Vaxillaire, Martine; Nilsson, Maria; More

Pharmacogenetics and Genomics. 18(11):967-975, November 2008.

Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin

Chen, Ligong; Pawlikowski, Bradley; Schlessinger, Avner; More

Pharmacogenetics and Genomics. 20(11):687-699, November 2010.

Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives

Haas, David W.; Cramer, Yoninah S.; Godfrey, Catherine; More

Pharmacogenetics and Genomics. 30(3):45-53, April 2020.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

Takahashi, Harumi; Wilkinson, Grant R.; Nutescu, Edith A.; More

Pharmacogenetics and Genomics. 16(2):101-110, February 2006.

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial

Serie, Daniel J.; Crook, Julia E.; Necela, Brian M.; More

Pharmacogenetics and Genomics. 27(10):378-385, October 2017.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Schmid, Yasmin; Vizeli, Patrick; Hysek, Cédric M.; More

Pharmacogenetics and Genomics. 26(8):397-401, August 2016.

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

Haufroid, Vincent; Mourad, Michel; Van Kerckhove, Valérie; More

Pharmacogenetics. 14(3):147-154, March 2004.

A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy

Kiyotani, Kazuma; Uno, Satoko; Mushiroda, Taisei; More

Pharmacogenetics and Genomics. 22(4):229-235, April 2012.

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

Tassaneeyakul, Wichittra; Jantararoungtong, Thawinee; Chen, Pei; More

Pharmacogenetics and Genomics. 19(9):704-709, September 2009.

Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism

Siccardi, Marco; D'Avolio, Antonio; Nozza, Silvia; More

Pharmacogenetics and Genomics. 20(12):759-765, December 2010.

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megías-Vericat, Juan E.; Montesinos, Pau; Herrero, María J.; More

Pharmacogenetics and Genomics. 27(7):270-274, July 2017.

International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing

Pereira, Naveen L.; So, Derek; Bae, Jang-Ho; More

Pharmacogenetics and Genomics. 29(4):76-83, June 2019.

A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Lonjou, Christine; Borot, Nicolas; Sekula, Peggy; More

Pharmacogenetics and Genomics. 18(2):99-107, February 2008.

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy

Jamieson, David; Cresti, Nicola; Bray, Johanne; More

Pharmacogenetics and Genomics. 21(12):808-819, December 2011.